India Wins Zero-Tariff Access for Speciality Drugs Under US Section 232 Exemption
核心洞察
The US Commerce Department (搜索) has listed India (搜索) among countries eligible for zero per cent tariffs on specified speciality pharmaceutical products and ingredients.
The exemption covers orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapies, gene therapies and antibody-drug conjugates.
A 100 per cent tariff on certain patented pharmaceutical imports takes effect September 29 for covered companies, after applying to others from July 31.
India (搜索) has been included among the countries eligible for zero US tariffs on several categories of speciality pharmaceutical products and ingredients, according to a US Commerce Department (搜索) notice published as Washington prepares to impose a 100 per cent tariff on certain patented pharmaceutical imports and their associated ingredients from September 29.
The relief is targeted rather than blanket. It applies only to specified medicines and ingredients covered by a presidential proclamation issued in April, and does not extend to every pharmaceutical product shipped from India (搜索).
Which products qualify
The eligible categories named in the notice include orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapies, gene therapies and antibody-drug conjugates. The exemption also covers certain medical countermeasures linked to chemical, biological, radiological and nuclear threats, along with some animal-health products.
India (搜索) was listed alongside Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, Britain and Vietnam.
According to the Commerce Department notice, qualifying products from these jurisdictions can receive a zero per cent tariff because the countries have a current or forthcoming trade and security framework agreement with the United States.
Section 232 mechanics and timing
The exemptions form part of the implementation of President Donald Trump's April proclamation adjusting imports of pharmaceuticals and pharmaceutical ingredients under Section 232 of the Trade Expansion Act. That proclamation introduced a 100 per cent tariff on specified patented pharmaceutical products and ingredients. It took effect on July 31 for companies identified in one annex and will apply to other covered companies from September 29.
The Commerce Department notice states that generic pharmaceutical products and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs. That distinction matters for India (搜索), where a large share of pharmaceutical exports to the United States consists of generic medicines, although Indian companies also manufacture patented products, active pharmaceutical ingredients and specialised therapies.
Why the carve-out matters for supply
India (搜索) is one of the world's largest manufacturers of generic medicines and a major supplier to the US healthcare system. Indian pharmaceutical companies also supply active pharmaceutical ingredients and finished formulations used by American hospitals, pharmacies and patients.
The exemption gives Indian manufacturers a defined route to preserve duty-free access for eligible high-value therapies, while the broader US tariff policy continues to encourage greater pharmaceutical manufacturing within the United States. Pharmaceutical trade remains an important component of the wider India (搜索)-US economic relationship.
The narrow exemption protects selected pharmaceutical and healthcare products from the new duties while leaving Washington's broader push to expand domestic drug production in place.